文献速递类风湿关节炎

RA风险期滑膜成纤维细胞存在DNA损伤且修复能力受损

RA-risk synovium exhibits DNA damage coupled with impaired DNA repair in fibroblasts.
PubMed 文献 · RMD Open · 2026-01-22

该研究探讨了类风湿关节炎(RA)患者及RA风险人群滑膜组织中的细胞DNA损伤与修复能力。结果显示,在临床前RA风险阶段,滑膜成纤维细胞和T细胞中已存在DNA损伤,且RA风险个体和RA患者的滑膜成纤维细胞DNA损伤增加、修复能力降低。senolytic药物在体外部分恢复了RA及RA风险滑膜成纤维细胞的DNA修复能力。

要点

  • 临床前RA风险阶段滑膜成纤维细胞和T细胞已出现DNA损伤。
  • RA风险个体及RA患者滑膜成纤维细胞DNA损伤增加且修复能力降低。
  • senolytic药物体外部分恢复RA及RA风险滑膜成纤维细胞的DNA修复能力。

核心结论

  • RA临床前阶段滑膜组织和成纤维细胞中存在持续性DNA损伤,可能参与疾病进展。
  • senolytic治疗可部分恢复滑膜成纤维细胞的DNA修复能力,提示其作为RA风险个体预防性治疗的潜在靶点。

研究设计与样本

  • 研究对RA不同阶段的滑膜活检组织和滑膜成纤维细胞进行免疫荧光染色检测γH2AX,并对培养的滑膜成纤维细胞进行DNA修复蛋白的定量PCR检测。

主要发现

  • 在临床前RA风险阶段,滑膜成纤维细胞和T细胞中均存在DNA损伤。
  • 与对照个体相比,RA风险个体和RA患者的培养滑膜成纤维细胞DNA损伤增加且DNA修复能力降低。
  • senolytic药物处理在体外部分恢复了RA和RA风险滑膜成纤维细胞的DNA损伤修复能力。

临床怎么用

  • 对于RA风险个体,滑膜成纤维细胞的DNA损伤和修复能力可能作为预防性治疗的评估靶点。
  • senolytic药物可能用于RA风险个体的预防性治疗,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive arthritis development. Persistent DNA damage in tissues is known to drive a senescent microenvironment, genomic instability and ultimately chronic inflammation. Here, we determined cellular DNA damage and repair capacity within synovial tissue from rheumatoid arthritis (RA) patients and individuals at risk of developing RA. METHODS: We investigated the presence of senescence-associated DNA damage in synovial biopsies and synovial fibroblasts obtained during different phases of RA. Histone 2A is phosphorylated (γH2AX) at the site of a double-stranded DNA break where DNA repair proteins are recruited and is therefore a proxy measurement for DNA damage. In this study, we employed immunofluorescence staining for γH2AX on synovial tissue sections and cultured synovial fibroblasts alongside quantitative PCR for a panel of DNA repair proteins. RESULTS: We demonstrated the presence of DNA damage in both synovial fibroblasts and T cells during the preclinical, RA-risk phase of disease. Furthermore, cultured synovial fibroblasts from RA-risk individuals and RA patients exhibited increased DNA damage and a reduced capacity for DNA repair compared with synovial fibroblasts from control individuals. Finally, treatment with senolytic drugs partially restored the DNA damage repair capacity in RA and RA-risk synovial fibroblasts in vitro. CONCLUSIONS: Our findings reveal persistent DNA damage in the preclinical phase of RA in both synovial tissue and fibroblasts, suggesting a role in disease progression. The partial restoration of DNA repair in synovial fibroblasts by senolytic treatment highlights its potential therapeutic target for preventative therapy in RA-risk individuals.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. O'Byrne AM, de Jong TA, Semmelink JF, et al. RA-risk synovium exhibits DNA damage coupled with impaired DNA repair in fibroblasts. RMD Open. 2026. PMID: 41571322. doi:10.1136/rmdopen-2025-005774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。